Various LC-MS/MS and RP-HPLC methods are reported in the literature for the estimation of barnidipine individually. According to the literature survey, there is no regulatory method reported for the estimation of barnidipine by LC-MS/MS in human plasma either in literature and pharmacopeia. Hence, in this study a Novel LC/MS/MS method was optimized and validated for simultaneous estimation and validation of barnidipine in human plasma in accordance with the USFDA, EMEA and other relevant regulatory guidelines. Bamidipine is an anti-hypertensive drug belonging to the dihydropyridine (DHP) group of calcium antagonists. It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20 mg. Bamidipine has selective action against cardiovascular calcium antagonist receptors and its anti-hypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action. The clinical anti-hypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and anti-hypertensives belonging to other drug classes such as atenolol and enalapril. Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients. Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as a headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with amlodipine and nitrendipine. Its use is not associated with reflex tachycardia. The validated regulatory bioanalytical method for estimation of barnidipine by LC-MS/MS in human plasma is useful for analysis of subject samples to support generic ANDA applications for different regulatory authorities for introducing new generic drugs in affordable rates for the patients. Also the validated regulatory method would be used as supporting literature for developing and validating better method in CROs and clinical research organizations to support new generic drugs.
INTRODUCTION
Barnidipine is an antihypertensive drug belonging to the di-hydropyridine (DHP) group of calcium antagonists. It is available in a modified-release formulation which has a gradual onset of action and is effective in a single daily oral dose of 10 to 20 mg. Barnidipine has selective action against cardiovascular calcium antagonist receptors and its antihypertensive action is related to the reduction of peripheral vascular resistance secondary to its vasodilatory action 1 . The clinical antihypertensive efficacy of barnidipine is similar to that of other DHP calcium antagonists such as nitrendipine and amlodipine, and anti-hypertensives belonging to other drug classes such as atenolol and enalapril. Barnidipine has been found to be as efficacious and well tolerated as hydrochlorothiazide in the management of hypertension in elderly patients. Barnidipine is generally well tolerated. As with other DHP calcium antagonists, vasodilator adverse events such as a headache, flushing and peripheral oedema account for most of the adverse events reported with its use and are usually transient. Oedema is less frequent than with
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Gopi Raju Talari and V. Kiran Kumar amlodipine and nitrendipine 2 . Its use is not associated with reflex tachycardia. Barnidipine is a white crystalline powder with a molecular weight of 491.53. It is slightly soluble in water. The experimental water solubility for Barnidipine is 2.89 mg/mL. Within the physiologic pH range, barnidipine is an ionized compound pKa=7.91 as strong base and pKa=19.47 as strong acid 3 . Mechanism of action barnidipine (pure S, S isomer) is a liphophilic 1, 4-dihydropyridine calcium antagonist showing high affinity for the calcium channels of the smooth muscle cells in the vascular wall. Receptor kinetics of barnidipine are characterized by a slow onset of action and a strong and long-lasting binding. The reduction in peripheral resistance brought about by barnidipine results in blood pressure lowering. When using barnidipine, the anti-hypertensive effect remains during the entire 24-hour dose interval 4 . Use of barnidipine in chronic treatment does not lead to an increase in basic heart frequency. The impact of barnidipine on cardiovascular morbidity or mortality has not been studied. However, recently completed, controlled studies of other long-acting dihydropyridines indicate similar beneficial effects on morbidity and mortality compared to other anti-hypertensives in hypertension of the elderly 5 . After repeated administration of libradin 20 to healthy individuals, the concomitant intake of food did not have a statistically significant effect on AUC, Cmax, Tmax or t½. Maximum plasma levels are obtained 5 to 6 hours after oral administration of Libradin 20. Libradin shows an absolute bioavailability of 1.1%. Barnidipine plasma concentrations may show considerable interpersonal variation 6, 7 . In-vitro studies show that barnidipine binds at the rate of 26-32% to human erythrocytes and to a high extent (89-95%) to plasma proteins. In-vitro analysis of protein components indicates that barnidipine mainly binds to serum albumin, followed by α1 acid glycoprotein and high-density lipoproteins. To a much lesser extent binding to γ globulin takes place 8, 9 . No drug interactions based on elimination of plasma protein binding have been observed in in-vitro studies. Barnidipine is to a great extent metabolized into inactive metabolites. No in-vivo chiral inversion of the pure S, S isomer takes place. Main reactions are N-debenzylisation of the side chain, hydrolysis of the N-benzylpyrrolidine ester, oxidation of the 1, 4-dihydropyridine ring, hydrolysis of the methyl ester and reduction of the nitro group. The metabolism of barnidipine seems mainly mediated by the CYP3A isoenzyme family. 10, 11 The median terminal elimination plasma half-life of libradin was 20 hours after repeated administration, according to a two-compartment analytical model. Elimination mainly takes place through metabolism. Barnidipine and/or its metabolites are excreted in faeces (60%), urine (40%) and breath (less than 1%). No un-metabolized barnidipine is excreted in urine 12 .
EXPERIMENTAL Instrumentation
Chromatography was performed with HPLC coupled with MS/MS. All HPLC systems were equipped with a column compartment with temperature control and an on-line degasser. Data acquisition, analysis, and reporting were performed by analyst chromatography software.
13-15
Reagents and Chemicals A pharmaceutically pure sample of barnidipine reference standard was obtained from clear synthetics, Hyderabad as gift samples along with their analytical reports. HPLC grade methanol, acetonitrile, diethyl ether and ammonium acetate was obtained from Merck chemical division, Mumbai. HPLC Waters used. Human plasma lots were local blood banks.
Chromatographic Condition
The isocratic mobile phase consisted of acetonitrile: 5mm ammonium acetate at 90:10 ratios at a flow rate of 1.0 mL min -1 (with splitter out/in 70:30) and ACE C18 5µ, 100mm X 4.6mm was used as stationary phase. The Mass parameters for barnidipine is 492.2/315.1 (m/z), barnidipine D5 is 497.4/315.1 (m/z).
Preparation of Working Standard Solutions
Spiking solutions were made and with serial dilution, the spiking solutions were spiked in the screened pooled matrix to Standard concentrations. 18, 19 Diluent/ Rinsing solution 800 mL of methanol was measured in a reagent bottle. Separately 200 mL of water measured and transferred to above-mentioned reagent bottle. The bottle was swirled to mix and sonicated for 5 minutes. Used within 4 days of preparation.
20, 21

mM Ammonium Acetate Solution
Weighed about 0.38540 gm of ammonium acetate and dissolved in 800 mL of water. Made up the volume to 1000 mL with water. Swirled the bottle to mix the contents. Sonicated for 5 minutes. Used within 4 days of preparation.
Mobile Phase
Measured100 mL of 5 mM Ammonium acetate buffer solution in a measuring cylinder. Separately measured 900 mL of Acetonitrile in a measuring cylinder. Transfer both the solution to a reagent bottle and swirl to mix the contents and sonicate for 5 minutes. Used within 4 days of preparation 22, 23 . Taken Internal Standard Stock Solution Barnidipine D5 (1000.000 µg/mL) Weighed accurately 2.000 mg Barnidipine D5 Reference standard transferred into a 2 mL volumetric flask. 1 mL of methanol was added and sonicated to aid dissolution. Volume made up to 2 mL with methanol to achieve the concentration 1000.000 µg/Ml.
Aqueous Standard Solution
24, 25
Intermediate Internal Standard Stock Solution Took 0.020 mL of ISTD stock solution (1000.000 µg/mL) into 10 mL volumetric flask and made up to volume with diluent to produce a concentration of 2.000 µg/mL. Stored in the refrigerator (2ºC to 8ºC).
Preparation of Internal Standard Dilution ((20.000 ng/mL))
Aliquoted volume 0.100 mL of ISTD INTM Stock solution into 10 mL volumetric flask and made up the volume with diluent. Provided a batch number. Stored in the refrigerator (2ºC to 8ºC). 26, 27 Vol. 
RESULTS AND DISCUSSION
Mass Spectroscopy
Various mobile phase combinations were tried initially to separate barnidipine on a C18 column. Preliminary experiments indicated that using different concentrations of acetonitrile or methanol with water was not able to separate the peaks of barnidipine or to obtain suitable retention and peak shape. In order to achieve acceptable peak shapes and get suitable run time for better separation, various buffer systems were tried systematically. Thereafter, acetonitrile:5mm ammonium Acetate (90:10 v/v) at flow rate of1.0mL min -1 (with splitter out/in 70:30),ACE C18 5µ, 100mm X 4.6mm was used as the mobile a n d stationary phase respectively to improve resolution, get short run time and reducing tailing of both peaks close to1. The mass parameters for barnidipine is 492.2/315.1 (m/z), barnidipine D5 is 497.4/315.1 (m/z). The retention time was found to be 1.750 ± 0.300 min for barnidipine and 1.730 ± 0.300 min for barnidipine D5.
Method Validation: System Suitability Test
System suitability test was performed by acquiring six consecutive injections from a single sample of the Highest Standard. The system was found to be sensitive, specific and reproducible for the current analytical run. Results are shown in Table- 
Sensitivity
Six replicate injections at LOQ level were injected to evaluate the sensitivity of the method. The limit of quantification (LOQ) was 25.580 pg/mL. Accuracy and precision at LOQ were 95.6% and 6.3% respectively, which were within the acceptance criteria of 80 -120% of nominal concentration for accuracy and 20% for precision shown in Table- 
Precision and Accuracy
The Intra day (P & A I) precision (% CV) for the low, dilution, middle and high-quality control samples ranged from 0.9% to 6.5%. The inter day precision ranged from 1.8% to 4.3%, which were within the acceptance criteria of 15% in Table- 13. The Intra day (P & A I) precision (% CV) for the limit of quantification quality control samples was 4.9%. The inter day precision was 5.0%, which were within the acceptance criteria of 20% in Table- 
Recovery
The mean areas of extracted quality control plasma samples of Barnidipine were compared against the mean areas of post extracted quality control samples of HOC, MQC and LQC. The % recovery at HQC, MQC and LQC levels were 84.0%, 86.5% and 85.9% respectively. Global recovery for Barnidipine was 85.5%, which were within the acceptance criteria of 115% shown in Table- 14.
The mean areas of extracted quality control plasma samples of ISTD (Barnidipine-D5) were compared to the internal standard mean areas of the post extracted quality control samples. Recovery for ISTD (Barnidipine-D5) is 48.8% which was within the acceptance criteria of 115% shown in Table- 
CONCLUSION
The validated regulatory bioanalytical method for estimation of Barnidipine by LC-MS/MS in human plasma is useful for analysis of subject samples to support generic ANDA applications for different regulatory authorities for introducing new generic drugs in affordable rates for the patients. Also the validated regulatory method would be used as supporting literature for developing and validating better method in CROs and clinical research organizations to support new generic drugs.
